Sanjay Malhotra, MD
Cardiovascular Disease · Las Vegas, NVNPI 1548280084
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Astellas Pharma US Inc at 41.0% of the total. Reporting peaked in 2019 at $18,218 and has fallen 86.7% since, to $2,428 in 2025. Among cardiovascular disease clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 567 payments — averaging $71.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$17K
- AstraZeneca$9K
- Biotronik Inc.$3K
- Medtronic$1K
- Amgen$1K
- Novartis$1K
- plus $8K from 30 others
Across 23 payments — averaging $2618.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$33K
- Amgen$24K
- Cvrx, Inc.$4K
What the payments were for
- Consulting fees$1,3953%
- Speaking & faculty fees$24,22559%
- Travel & lodging$2,3406%
- Food & beverage$12,68631%
- Education$430%
- Gifts$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 24 | $16,730 |
| AstraZeneca | 18 | $9,167 |
| Biotronik Inc. | 7 | $2,915 |
| Medtronic(2 entities) | 32 | $1,496 |
| Amgen | 122 | $1,417 |
| Novartis | 72 | $1,215 |
| Pfizer | 28 | $1,072 |
| Johnson & Johnson(2 entities) | 72 | $988 |
| E.r. Squibb & Sons, L.L.C. | 44 | $671 |
| Heartflow, Inc. | 6 | $478 |
| Boston Scientific | 14 | $472 |
| Penumbra, Inc. | 6 | $459 |
| Bridgebio Pharma, Inc. | 10 | $411 |
| Abbott | 6 | $358 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $330 |
| Merck | 12 | $278 |
| Cvrx, Inc. | 2 | $271 |
| Cleerly, Inc. | 4 | $266 |
| Lexicon Pharmaceuticals, Inc. | 12 | $262 |
| Alnylam Pharmaceuticals Inc. | 10 | $213 |
| Sanofi-aventis U.S. LLC | 10 | $190 |
| Abiomed | 6 | $176 |
| Bayer | 4 | $170 |
| Edwards Lifesciences | 3 | $163 |
| Chiesi USA, Inc. | 1 | $84 |
| Boehringer Ingelheim | 4 | $81 |
| Regeneron Healthcare Solutions, Inc. | 4 | $79 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $68 |
| Impulse Dynamics (USA) Inc. | 1 | $52 |
| Esperion Therapeutics, Inc. | 3 | $51 |
| Amarin Pharma, Inc. | 3 | $42 |
| Kestra Medical Technology Services, Inc. | 1 | $41 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Biotronik NRO, Inc. | 1 | $28 |
| AbbVie | 1 | $24 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRILINTA$8,870
- VYNDAQEL$700
- Repatha$364
- SYMPLICITY G3$317
- Barostim Neo System$271
- Indigo$244
- FFRct$238
- TurboHawk$175
- FFRangio$174
- GENERAL ULTRASOUND$174
- Attruby$143
- Edwards SAPIEN 3 Transcatheter Heart Valve$132
- CARDIOMEMS$131
- Cleerly Ischemia$129
- Cleerly Labs$129
- Penumbra System$127
- Adempas$112
- AVEIR$104
How this compares
$40,773 in reported general payments places this provider in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 480 | $587,729 |
| XareltoRivaroxaban | 219 | $250,003 |
| EntrestoSacubitril/Valsartan | 193 | $194,928 |
| CamzyosMavacamten | 21 | $174,001 |
| Repatha SureclickEvolocumab | 174 | $171,282 |
| BrilintaTicagrelor | 62 | $65,069 |
| FarxigaDapagliflozin Propanediol | 49 | $54,405 |
| MultaqDronedarone Hcl | 23 | $37,324 |
| JardianceEmpagliflozin | 16 | $27,938 |
| Praluent PenAlirocumab | 23 | $22,291 |
| Ranolazine ErRanolazine | 158 | $18,473 |
| VascepaIcosapent Ethyl | 23 | $12,443 |
| Atorvastatin Calcium | 639 | $6,735 |
| Rosuvastatin Calcium | 383 | $6,078 |
| Carvedilol | 571 | $5,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,072 | $587,729480 claims |
| Johnson & JohnsonXarelto | $988 | $250,003219 claims |
| NovartisEntresto | $1,215 | $194,928193 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $671 | $174,00121 claims |
| AstraZenecaBrilinta, Farxiga | $9,167 | $119,474111 claims |
| Sanofi-aventis U.S. LLCMultaq | $190 | $37,32423 claims |
| Boehringer IngelheimJardiance | $81 | $27,93816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
- Dalia HawwassLas Vegas$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.